• About us
• Contact

Advertisement

Product › Details

bispecific antibody

	Next higher product group	antibody
	Status	1995-01-01 development existent
	Organisation	Medarex Inc. (Nasdaq: MEDX)
	Group	Bristol Myers Squibb (BMS) (Group)

Record changed: 2024-12-03

Advertisement

More documents for bispecific antibody

• [1] Sotio Biotech a.s.. (7/16/24). "Press Release: Sotio Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline". Prague & Beijing....
• [2] Biotheus Inc.. (11/6/23). "Press Release: Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications". Zhuhai....
• [3] FyoniBio GmbH. (10/20/22). "Press Release: FyoniBio and Strike Pharma Sign a Master Service Agreement Covering Cell Line Development for a Novel Bi-specific Therapeutic mAb". Berlin & Stockholm....
• [4] Immunocore Holdings plc. (7/18/22). "Press Release: Immunocore Announces $140 Million Private Placement Financing". Oxfordshire, Conshohocken, PA & Rockville, MD....
• [5] F-Star Therapeutics, Inc.. (6/23/22). "Press Release: invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs". London....
• [6] F-Star Therapeutics Ltd.. (10/20/21). "Press Release: F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics". Cambridge & Cambridge, MA....
• [7] Immunocore Holdings plc. (2/16/21). "Press Release: Immunocore Announces Key Appointments to Management and Board". Oxfordshire & Conshohocken, PA....
• [8] Biomunex Pharmaceuticals SASU. (2/16/21). "Press Release: Biomunex Pharmaceuticals Signs Strategic License and Co-Development Agreement with Onward Therapeutics for Proprietary Bispecific Antibody Program". Paris & Cambridge, MA....
• [9] Immunocore Holdings plc. (2/9/21). "Press Release: Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0 Million Concurrent...
• [10] Merus N.V.. (1/21/21). "Press Release: Merus Announces Pricing of Public Offering of Common Shares". Utrecht & Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.